Table 3.

Treatment-emergent adverse events considered to be related to study treatment.

	Low-Dose HD-MAP n = 16 n (%) [e]	High-Dose HD-MAP n = 16 n (%) [e]	Uncoated HD-MAP n = 16 n (%) [e]	MR-Vac n = 15 n (%) [e]
Systemic
Fatigue	0	1 (6.3) [1]	0	0
Arthralgia	0	0	0	1 (6.7) [1]
Myalgia	0	0	0	1 (6.7) [1]
Headache	0	2 (12.5) [2]	2 (12.5) [2]	1 (6.7) [2]
Local
Application site exfoliation	1 (6.3) [1]	0	1 (6.3) [1]	0
Injection site pain	1 (6.3) [1]	2 (12.5) [2]	1 (6.3) [1]	3 (20.0) [3]
Injection site pruritus	3 (18.8) [3]	6 (37.5) [7]	0	0

Note: For each AE, the results are presented as the number of subjects with the event, n; the proportion of subjects with the event, (%); and the number of events, [e].